Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

8.540 +0.390 (+4.79%)
Streaming Delayed Price Updated: 12:49 PM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relay Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative... 
Via MarketMinute
Topics ETFs Government Initial Public Offering
News headline image
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Preview: Relay Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Relay Therapeutics Director Sells $300,000 Worth of Shares. Here's Why Investors Shouldn't Panic. ↗
Sometimes insiders sell shares because their conviction is changing. Sometimes it's just about bookkeeping. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗
Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture
Artificial intelligence, often spotlighted for its advancements in mainstream applications like conversational agents and autonomous vehicles, is quietly orchestrating a profound transformation across... 
Via TokenRing AI
Topics Artificial Intelligence Economy Emissions
News headline image
Relay Therapeutics Inc (NASDAQ:RLAY) Reports Q3 2025 Earnings Miss and Clinical Progress ↗
Relay Therapeutics reports Q3 2025 results, missing revenue estimates. The biotech firm maintains a strong cash position to fund its clinical trials for lead drug RLY-2608 into 2029. 
Via Chartmill
Topics Earnings
News headline image
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week ↗
The cancer-focused biotech has a bright future, according to one pundit. 
Via The Motley Fool
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Medtronic To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Relay (RLAY) Q2 Loss Narrows 41% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.